APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilars Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Biosimilars Drug Market Analysis and Forecast 2026-2032

21 December 2025215 pages

Choose your research edition.

Industry ResearchBiosimilars Drug Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilars Drug Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Biosimilars Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilars Drug Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilars Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Biosimilars Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Biosimilars Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Biosimilars Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Biosimilars Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Biosimilars Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Biosimilars Drug include Sanofi, Qilu Pharmaceutical, Novartis, Eli Lilly, Pfizer, Zhejiang Hisun, Wockhardt, United Laboratory and Tonghua Dongbao, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Biosimilars Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biosimilars Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Biosimilars Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilars Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biosimilars Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Biosimilars Drug revenue, projected growth trends, production technology, application and end-user industry.

Biosimilars Drug Segment by Company

Sanofi

Qilu Pharmaceutical

Novartis

Eli Lilly

Pfizer

Zhejiang Hisun

Wockhardt

United Laboratory

Tonghua Dongbao

Shanghai Henlius

Luye Pharma

Jiangsu Hengrui

Innovent Biologics

Geropharm

Gan&Lee

Dr Reddy’s

Celltrion

Celgen Biopharma

Bio-Thera

Biocon

3SBIO

Biosimilars Drug Segment by Type

Monoclonal Antibodies

Insulin

Others

Biosimilars Drug Segment by Application

Hospital

Retail Pharmacy

Other

Biosimilars Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilars Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Biosimilars Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Biosimilars Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilars Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biosimilars Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Monoclonal Antibodies Major Player Table 3. Insulin Major Player Table 4. Others Major Player Table 5. Global Biosimilars Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Retail Pharmacy Major Player Table 8. Other Major Player Table 9. Biosimilars Drug Industry Trends Table 10. Biosimilars Drug Industry Drivers Table 11. Biosimilars Drug Industry Opportunities and Challenges Table 12. Biosimilars Drug Industry Restraints Table 13. Global Biosimilars Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Biosimilars Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Biosimilars Drug Market Share by Region (2021-2026) Table 16. Global Biosimilars Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Biosimilars Drug Market Share by Region (2027-2032) Table 18. Global Biosimilars Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Biosimilars Drug Revenue Market Share by Players (2021-2026) Table 20. Global Biosimilars Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Biosimilars Drug Key Players Headquarters & Area Served Table 22. Global Biosimilars Drug Players, Product Type & Application Table 23. Global Biosimilars Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Biosimilars Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Biosimilars Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Biosimilars Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Biosimilars Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Biosimilars Drug Revenue Market Share by Type (2021-2026) Table 30. Global Biosimilars Drug Revenue Market Share by Type (2027-2032) Table 31. Global Biosimilars Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Biosimilars Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Biosimilars Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Biosimilars Drug Revenue Market Share by Application (2021-2026) Table 35. Global Biosimilars Drug Revenue Market Share by Application (2027-2032) Table 36. Sanofi Company Information Table 37. Sanofi Business Overview Table 38. Sanofi Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sanofi Biosimilars Drug Product Portfolio Table 40. Sanofi Recent Development Table 41. Qilu Pharmaceutical Company Information Table 42. Qilu Pharmaceutical Business Overview Table 43. Qilu Pharmaceutical Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Qilu Pharmaceutical Biosimilars Drug Product Portfolio Table 45. Qilu Pharmaceutical Recent Development Table 46. Novartis Company Information Table 47. Novartis Business Overview Table 48. Novartis Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Novartis Biosimilars Drug Product Portfolio Table 50. Novartis Recent Development Table 51. Eli Lilly Company Information Table 52. Eli Lilly Business Overview Table 53. Eli Lilly Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Eli Lilly Biosimilars Drug Product Portfolio Table 55. Eli Lilly Recent Development Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Pfizer Biosimilars Drug Product Portfolio Table 60. Pfizer Recent Development Table 61. Zhejiang Hisun Company Information Table 62. Zhejiang Hisun Business Overview Table 63. Zhejiang Hisun Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Zhejiang Hisun Biosimilars Drug Product Portfolio Table 65. Zhejiang Hisun Recent Development Table 66. Wockhardt Company Information Table 67. Wockhardt Business Overview Table 68. Wockhardt Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Wockhardt Biosimilars Drug Product Portfolio Table 70. Wockhardt Recent Development Table 71. United Laboratory Company Information Table 72. United Laboratory Business Overview Table 73. United Laboratory Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. United Laboratory Biosimilars Drug Product Portfolio Table 75. United Laboratory Recent Development Table 76. Tonghua Dongbao Company Information Table 77. Tonghua Dongbao Business Overview Table 78. Tonghua Dongbao Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Tonghua Dongbao Biosimilars Drug Product Portfolio Table 80. Tonghua Dongbao Recent Development Table 81. Shanghai Henlius Company Information Table 82. Shanghai Henlius Business Overview Table 83. Shanghai Henlius Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Shanghai Henlius Biosimilars Drug Product Portfolio Table 85. Shanghai Henlius Recent Development Table 86. Luye Pharma Company Information Table 87. Luye Pharma Business Overview Table 88. Luye Pharma Biosimilars Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Luye Pharma Biosimilars Drug Product Portfolio Table 90. Luye Pharma Recent Development Table 91. Jiangsu Hengrui Company Information Table 92. Jiangsu Hengrui Business Overview Table 93. Jiangsu Hengrui Biosimilars Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Jiangsu Hengrui Biosimilars Drug Product Portfolio Table 95. Jiangsu Hengrui Recent Development Table 96. Innovent Biologics Company Information Table 97. Innovent Biologics Business Overview Table 98. Innovent Biologics Biosimilars Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Innovent Biologics Biosimilars Drug Product Portfolio Table 100. Innovent Biologics Recent Development Table 101. Geropharm Company Information Table 102. Geropharm Business Overview Table 103. Geropharm Biosimilars Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Geropharm Biosimilars Drug Product Portfolio Table 105. Geropharm Recent Development Table 106. Gan&Lee Company Information Table 107. Gan&Lee Business Overview Table 108. Gan&Lee Biosimilars Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Gan&Lee Biosimilars Drug Product Portfolio Table 110. Gan&Lee Recent Development Table 111. Dr Reddy’s Company Information Table 112. Dr Reddy’s Business Overview Table 113. Dr Reddy’s Biosimilars Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Dr Reddy’s Biosimilars Drug Product Portfolio Table 115. Dr Reddy’s Recent Development Table 116. Celltrion Company Information Table 117. Celltrion Business Overview Table 118. Celltrion Biosimilars Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Celltrion Biosimilars Drug Product Portfolio Table 120. Celltrion Recent Development Table 121. Celgen Biopharma Company Information Table 122. Celgen Biopharma Business Overview Table 123. Celgen Biopharma Biosimilars Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Celgen Biopharma Biosimilars Drug Product Portfolio Table 125. Celgen Biopharma Recent Development Table 126. Bio-Thera Company Information Table 127. Bio-Thera Business Overview Table 128. Bio-Thera Biosimilars Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Bio-Thera Biosimilars Drug Product Portfolio Table 130. Bio-Thera Recent Development Table 131. Biocon Company Information Table 132. Biocon Business Overview Table 133. Biocon Biosimilars Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Biocon Biosimilars Drug Product Portfolio Table 135. Biocon Recent Development Table 136. 3SBIO Company Information Table 137. 3SBIO Business Overview Table 138. 3SBIO Biosimilars Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. 3SBIO Biosimilars Drug Product Portfolio Table 140. 3SBIO Recent Development Table 141. North America Biosimilars Drug Revenue by Type (2021-2026) & (US$ Million) Table 142. North America Biosimilars Drug Revenue by Type (2027-2032) & (US$ Million) Table 143. North America Biosimilars Drug Revenue by Application (2021-2026) & (US$ Million) Table 144. North America Biosimilars Drug Revenue by Application (2027-2032) & (US$ Million) Table 145. North America Biosimilars Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. North America Biosimilars Drug Revenue by Country (2021-2026) & (US$ Million) Table 147. North America Biosimilars Drug Revenue by Country (US$ Million) & (2027-2032) Table 148. Europe Biosimilars Drug Revenue by Type (2021-2026) & (US$ Million) Table 149. Europe Biosimilars Drug Revenue by Type (2027-2032) & (US$ Million) Table 150. Europe Biosimilars Drug Revenue by Application (2021-2026) & (US$ Million) Table 151. Europe Biosimilars Drug Revenue by Application (2027-2032) & (US$ Million) Table 152. Europe Biosimilars Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 153. Europe Biosimilars Drug Revenue by Country (2021-2026) & (US$ Million) Table 154. Europe Biosimilars Drug Revenue by Country (US$ Million) & (2027-2032) Table 155. China Biosimilars Drug Revenue by Type (2021-2026) & (US$ Million) Table 156. China Biosimilars Drug Revenue by Type (2027-2032) & (US$ Million) Table 157. China Biosimilars Drug Revenue by Application (2021-2026) & (US$ Million) Table 158. China Biosimilars Drug Revenue by Application (2027-2032) & (US$ Million) Table 159. Asia Biosimilars Drug Revenue by Type (2021-2026) & (US$ Million) Table 160. Asia Biosimilars Drug Revenue by Type (2027-2032) & (US$ Million) Table 161. Asia Biosimilars Drug Revenue by Application (2021-2026) & (US$ Million) Table 162. Asia Biosimilars Drug Revenue by Application (2027-2032) & (US$ Million) Table 163. Asia Biosimilars Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 164. Asia Biosimilars Drug Revenue by Region (US$ Million) & (2021-2026) Table 165. Asia Biosimilars Drug Revenue by Region (US$ Million) & (2027-2032) Table 166. SAMEA Biosimilars Drug Revenue by Type (2021-2026) & (US$ Million) Table 167. SAMEA Biosimilars Drug Revenue by Type (2027-2032) & (US$ Million) Table 168. SAMEA Biosimilars Drug Revenue by Application (2021-2026) & (US$ Million) Table 169. SAMEA Biosimilars Drug Revenue by Application (2027-2032) & (US$ Million) Table 170. SAMEA Biosimilars Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. SAMEA Biosimilars Drug Revenue by Country (2021-2026) & (US$ Million) Table 172. SAMEA Biosimilars Drug Revenue by Country (US$ Million) & (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Biosimilars Drug Image Figure 2. Global Biosimilars Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilars Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Monoclonal Antibodies Image Figure 5. Insulin Image Figure 6. Others Image Figure 7. Global Biosimilars Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Biosimilars Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Retail Pharmacy Image Figure 11. Other Image Figure 12. Global Biosimilars Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global Biosimilars Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Biosimilars Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Biosimilars Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Biosimilars Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Biosimilars Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Biosimilars Drug Revenue Market Share by Type (2021-2032) Figure 20. Global Biosimilars Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Biosimilars Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Biosimilars Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Biosimilars Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Biosimilars Drug Revenue Share by Type (2021-2032) Figure 25. North America Biosimilars Drug Revenue Share by Application (2021-2032) Figure 26. North America Biosimilars Drug Revenue Share by Country (2021-2032) Figure 27. United States Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Biosimilars Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Biosimilars Drug Revenue Share by Type (2021-2032) Figure 32. Europe Biosimilars Drug Revenue Share by Application (2021-2032) Figure 33. Europe Biosimilars Drug Revenue Share by Country (2021-2032) Figure 34. Germany Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Biosimilars Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Biosimilars Drug Revenue Share by Type (2021-2032) Figure 44. China Biosimilars Drug Revenue Share by Application (2021-2032) Figure 45. Asia Biosimilars Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Biosimilars Drug Revenue Share by Type (2021-2032) Figure 47. Asia Biosimilars Drug Revenue Share by Application (2021-2032) Figure 48. Asia Biosimilars Drug Revenue Share by Region (2021-2032) Figure 49. Japan Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Biosimilars Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Biosimilars Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA Biosimilars Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA Biosimilars Drug Revenue Share by Country (2021-2032) Figure 59. Brazil Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Biosimilars Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Insulin
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Sanofi
  • Qilu Pharmaceutical
  • Novartis
  • Eli Lilly
  • Pfizer
  • Zhejiang Hisun
  • Wockhardt
  • United Laboratory
  • Tonghua Dongbao
  • Shanghai Henlius
  • Luye Pharma
  • Jiangsu Hengrui
  • Innovent Biologics
  • Geropharm
  • Gan&Lee
  • Dr Reddy’s
  • Celltrion
  • Celgen Biopharma
  • Bio-Thera
  • Biocon
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biosimilars Drug Market by Type
  3. 1.2.1 Global Biosimilars Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Monoclonal Antibodies
  5. 1.2.3 Insulin
  6. 1.2.4 Others
  7. 1.3 Biosimilars Drug Market by Application
  8. 1.3.1 Global Biosimilars Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Retail Pharmacy
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Biosimilars Drug Market Dynamics
  1. 2.1 Biosimilars Drug Industry Trends
  2. 2.2 Biosimilars Drug Industry Drivers
  3. 2.3 Biosimilars Drug Industry Opportunities and Challenges
  4. 2.4 Biosimilars Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Biosimilars Drug Market Perspective (2021-2032)
  2. 3.2 Global Biosimilars Drug Growth Trends by Region
  3. 3.2.1 Global Biosimilars Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biosimilars Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Biosimilars Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Biosimilars Drug Revenue by Players
  2. 4.1.1 Global Biosimilars Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Biosimilars Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Biosimilars Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biosimilars Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Biosimilars Drug Key Players Headquarters & Area Served
  7. 4.4 Global Biosimilars Drug Players, Product Type & Application
  8. 4.5 Global Biosimilars Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Biosimilars Drug Market CR5 and HHI
  11. 4.6.3 2025 Biosimilars Drug Tier 1, Tier 2, and Tier 3
5 Biosimilars Drug Market Size by Type
  1. 5.1 Global Biosimilars Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Biosimilars Drug Revenue by Type (2021-2032)
  3. 5.3 Global Biosimilars Drug Revenue Market Share by Type (2021-2032)
6 Biosimilars Drug Market Size by Application
  1. 6.1 Global Biosimilars Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Biosimilars Drug Revenue by Application (2021-2032)
  3. 6.3 Global Biosimilars Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Biosimilars Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Biosimilars Drug Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Qilu Pharmaceutical
  8. 7.2.1 Qilu Pharmaceutical Company Information
  9. 7.2.2 Qilu Pharmaceutical Business Overview
  10. 7.2.3 Qilu Pharmaceutical Biosimilars Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Qilu Pharmaceutical Biosimilars Drug Product Portfolio
  12. 7.2.5 Qilu Pharmaceutical Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Biosimilars Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Biosimilars Drug Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Eli Lilly
  20. 7.4.1 Eli Lilly Company Information
  21. 7.4.2 Eli Lilly Business Overview
  22. 7.4.3 Eli Lilly Biosimilars Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly Biosimilars Drug Product Portfolio
  24. 7.4.5 Eli Lilly Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Biosimilars Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Biosimilars Drug Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Zhejiang Hisun
  32. 7.6.1 Zhejiang Hisun Company Information
  33. 7.6.2 Zhejiang Hisun Business Overview
  34. 7.6.3 Zhejiang Hisun Biosimilars Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Zhejiang Hisun Biosimilars Drug Product Portfolio
  36. 7.6.5 Zhejiang Hisun Recent Developments
  37. 7.7 Wockhardt
  38. 7.7.1 Wockhardt Company Information
  39. 7.7.2 Wockhardt Business Overview
  40. 7.7.3 Wockhardt Biosimilars Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Wockhardt Biosimilars Drug Product Portfolio
  42. 7.7.5 Wockhardt Recent Developments
  43. 7.8 United Laboratory
  44. 7.8.1 United Laboratory Company Information
  45. 7.8.2 United Laboratory Business Overview
  46. 7.8.3 United Laboratory Biosimilars Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 United Laboratory Biosimilars Drug Product Portfolio
  48. 7.8.5 United Laboratory Recent Developments
  49. 7.9 Tonghua Dongbao
  50. 7.9.1 Tonghua Dongbao Company Information
  51. 7.9.2 Tonghua Dongbao Business Overview
  52. 7.9.3 Tonghua Dongbao Biosimilars Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Tonghua Dongbao Biosimilars Drug Product Portfolio
  54. 7.9.5 Tonghua Dongbao Recent Developments
  55. 7.10 Shanghai Henlius
  56. 7.10.1 Shanghai Henlius Company Information
  57. 7.10.2 Shanghai Henlius Business Overview
  58. 7.10.3 Shanghai Henlius Biosimilars Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Shanghai Henlius Biosimilars Drug Product Portfolio
  60. 7.10.5 Shanghai Henlius Recent Developments
  61. 7.11 Luye Pharma
  62. 7.11.1 Luye Pharma Company Information
  63. 7.11.2 Luye Pharma Business Overview
  64. 7.11.3 Luye Pharma Biosimilars Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Luye Pharma Biosimilars Drug Product Portfolio
  66. 7.11.5 Luye Pharma Recent Developments
  67. 7.12 Jiangsu Hengrui
  68. 7.12.1 Jiangsu Hengrui Company Information
  69. 7.12.2 Jiangsu Hengrui Business Overview
  70. 7.12.3 Jiangsu Hengrui Biosimilars Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Jiangsu Hengrui Biosimilars Drug Product Portfolio
  72. 7.12.5 Jiangsu Hengrui Recent Developments
  73. 7.13 Innovent Biologics
  74. 7.13.1 Innovent Biologics Company Information
  75. 7.13.2 Innovent Biologics Business Overview
  76. 7.13.3 Innovent Biologics Biosimilars Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Innovent Biologics Biosimilars Drug Product Portfolio
  78. 7.13.5 Innovent Biologics Recent Developments
  79. 7.14 Geropharm
  80. 7.14.1 Geropharm Company Information
  81. 7.14.2 Geropharm Business Overview
  82. 7.14.3 Geropharm Biosimilars Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Geropharm Biosimilars Drug Product Portfolio
  84. 7.14.5 Geropharm Recent Developments
  85. 7.15 Gan&Lee
  86. 7.15.1 Gan&Lee Company Information
  87. 7.15.2 Gan&Lee Business Overview
  88. 7.15.3 Gan&Lee Biosimilars Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Gan&Lee Biosimilars Drug Product Portfolio
  90. 7.15.5 Gan&Lee Recent Developments
  91. 7.16 Dr Reddy’s
  92. 7.16.1 Dr Reddy’s Company Information
  93. 7.16.2 Dr Reddy’s Business Overview
  94. 7.16.3 Dr Reddy’s Biosimilars Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Dr Reddy’s Biosimilars Drug Product Portfolio
  96. 7.16.5 Dr Reddy’s Recent Developments
  97. 7.17 Celltrion
  98. 7.17.1 Celltrion Company Information
  99. 7.17.2 Celltrion Business Overview
  100. 7.17.3 Celltrion Biosimilars Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Celltrion Biosimilars Drug Product Portfolio
  102. 7.17.5 Celltrion Recent Developments
  103. 7.18 Celgen Biopharma
  104. 7.18.1 Celgen Biopharma Company Information
  105. 7.18.2 Celgen Biopharma Business Overview
  106. 7.18.3 Celgen Biopharma Biosimilars Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Celgen Biopharma Biosimilars Drug Product Portfolio
  108. 7.18.5 Celgen Biopharma Recent Developments
  109. 7.19 Bio-Thera
  110. 7.19.1 Bio-Thera Company Information
  111. 7.19.2 Bio-Thera Business Overview
  112. 7.19.3 Bio-Thera Biosimilars Drug Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Bio-Thera Biosimilars Drug Product Portfolio
  114. 7.19.5 Bio-Thera Recent Developments
  115. 7.20 Biocon
  116. 7.20.1 Biocon Company Information
  117. 7.20.2 Biocon Business Overview
  118. 7.20.3 Biocon Biosimilars Drug Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Biocon Biosimilars Drug Product Portfolio
  120. 7.20.5 Biocon Recent Developments
  121. 7.21 3SBIO
  122. 7.21.1 3SBIO Company Information
  123. 7.21.2 3SBIO Business Overview
  124. 7.21.3 3SBIO Biosimilars Drug Revenue and Gross Margin (2021-2026)
  125. 7.21.4 3SBIO Biosimilars Drug Product Portfolio
  126. 7.21.5 3SBIO Recent Developments
8 North America
  1. 8.1 North America Biosimilars Drug Revenue (2021-2032)
  2. 8.2 North America Biosimilars Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Biosimilars Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Biosimilars Drug Revenue by Type (2027-2032)
  5. 8.3 North America Biosimilars Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Biosimilars Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Biosimilars Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Biosimilars Drug Revenue by Application (2027-2032)
  9. 8.5 North America Biosimilars Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Biosimilars Drug Revenue by Country
  11. 8.6.1 North America Biosimilars Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Biosimilars Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Biosimilars Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Biosimilars Drug Revenue (2021-2032)
  2. 9.2 Europe Biosimilars Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Biosimilars Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Biosimilars Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Biosimilars Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Biosimilars Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Biosimilars Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Biosimilars Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Biosimilars Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Biosimilars Drug Revenue by Country
  11. 9.6.1 Europe Biosimilars Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Biosimilars Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Biosimilars Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Biosimilars Drug Revenue (2021-2032)
  2. 10.2 China Biosimilars Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Biosimilars Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Biosimilars Drug Revenue by Type (2027-2032)
  5. 10.3 China Biosimilars Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Biosimilars Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Biosimilars Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Biosimilars Drug Revenue by Application (2027-2032)
  9. 10.5 China Biosimilars Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biosimilars Drug Revenue (2021-2032)
  2. 11.2 Asia Biosimilars Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Biosimilars Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Biosimilars Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Biosimilars Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Biosimilars Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Biosimilars Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Biosimilars Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Biosimilars Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Biosimilars Drug Revenue by Country
  11. 11.6.1 Asia Biosimilars Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Biosimilars Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Biosimilars Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biosimilars Drug Revenue (2021-2032)
  2. 12.2 SAMEA Biosimilars Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Biosimilars Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Biosimilars Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Biosimilars Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Biosimilars Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Biosimilars Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Biosimilars Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Biosimilars Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Biosimilars Drug Revenue by Country
  11. 12.6.1 SAMEA Biosimilars Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Biosimilars Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Biosimilars Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst